Abstract:Marjan Kerkhof, 1 Jaco Voorham, 1 Paul Dorinsky, 2 Claudia Cabrera, 3, 4 Patrick Darken, 5 Janwillem WH Kocks, 1, 6 Mohsen Sadatsafavi, 7, 8 Don D Sin, 7, 8 Victoria Carter, 1 David B Price 1, 9 1 Observational & Pragmatic Research Institute Pte Ltd, Singapore, Singapore; 2 AstraZeneca, Durham, NC, USA; 3 AstraZeneca, Mölndal, Sweden; 4 Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden; 5 AstraZeneca, Morristown, NJ, USA; 6 General Practitioners Research Institute, Groningen, The Netherlands; 7 Respiratory Evaluation Sciences Program, Collaboration for Outcomes Research and Evaluation, University of British Columbia, Vancouver, BC, Canada; 8 Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, BC, Canada; 9 Academic Primary Care, University of Aberdeen, Aberdeen, UK Correspondence: David B Price Polwarth Building, Foresterhill, Aberdeen AB25 2ZD, UK Tel +65 6962 3627 Email dprice@opri.sg Introduction: Early identification of preventable risk factors of COPD progression is important. Whether exacerbations have a negative impact on disease progression is largely unknown. We investigated whether the long-term occurrence of exacerbations is associated with lung function decline at early stages of COPD. Methods: Patients diagnosed with mild/moderate COPD (obstruction and FEV 1 % predicted 50– 90%), aged ≥ 35 years, and a smoking history, who had ≥ 6 years of UK electronic medical records after initiation of maintenance therapy were studied. Multilevel mixed-effect linear regression was performed to determine the association between the count of any year in which the patient had ≥ 1 exacerbation over a 6-year period and FEV 1 decline, adjusted for sex, age, anthropometrics and smoking habits. Exacerbations were defined as any prescription for an acute oral corticosteroid course and/or lower respiratory-related antibiotics and/or any COPD-related emergency or inpatient hospitalization. Results: Of 11,337 patients included (mean age 65 years; 49% female) 31.6%, 23.3%, 16.6%, 11.6%, 8.1%, 5.3% and 3.4% had 0, 1, 2, 3, 4, 5 and 6 years with ≥ 1 exacerbation. The mean annual FEV 1 decline accelerated by 1.50 mL/year (95% Confidence Interval 1.02; 1.98) with every additional year with ≥ 1 exacerbation from 31.0 mL/year in subjects without any exacerbation to 40.0 mL/year in patients experiencing ≥ 1 exacerbation every year. Patients with more years with ≥ 1 exacerbation had a lower mean FEV 1 at first diagnosis: 14.7 mL (11.7; 17.8) lower with every additional year with exacerbations. When counting years with ≥ 2 exacerbations, greater effects were observed (2.19 [1.50; 2.88] mL/year excess decline per year with ≥ 2 exacerbations; 16.5 mL [12.1; 20.8] lower FEV 1 at diagnosis). Conclusion: Patients who experienced a greater exacerbation burden after initiation of maintenance therapy had worse lung function at diagnosis and a more rapid lung function decline thereafter, which emphasizes the need for better treatment strategies. Keywords: COPD, exacerbations, spirometry, inhalation therapy, observational study

Validation of exacerbation history grading by GOLD for predicting future COPD outcomes

Determining prognosis in acute exacerbation of COPD

Risk Factors for Recurrent Exacerbations in the General-Practitioner-Based Swiss Chronic Obstructive Pulmonary Disease (COPD) Cohort

Impact of exacerbation history on future risk and treatment outcomes in chronic obstructive pulmonary disease patients: A prospective cohort study based on Global Initiative for Chronic Obstructive Lung Disease (GOLD) A and B classifications

Exacerbation history and risk of myocardial infarction and pulmonary embolism in chronic obstructive pulmonary disease

Predicting exacerbations in COPD in the Danish general population

Development and validation of a prediction score to assess the risk of incurring in COPD-related exacerbations: a population-based study in primary care

Exacerbation history and blood eosinophil count prior to diagnosis of COPD and risk of subsequent exacerbations

Prediction of gold stage in patients hospitalized with COPD exacerbations using blood neutrophils and demographic parameters as risk factors

Utility of the Combination of Serum Highly-Sensitive C-reactive Protein Level at Discharge and a Risk Index in Predicting Readmission for Acute Exacerbation of COPD,

Predictors of Hospitalized Exacerbations and Mortality in Chronic Obstructive Pulmonary Disease

EXAcerbations of COPD and their OutcomeS on CardioVascular diseases (EXACOS-CV) Programme: protocol of multicountry observational cohort studies

Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease

COPD patients prescribed inhaled corticosteroid in primary care: time for re-assessment based on exacerbation rate and blood eosinophils?

Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study

Prediction Of Short Term Re-Exacerbation In Patients With Acute Exacerbation Of Chronic Obstructive Pulmonary Disease

Association between COPD exacerbations and lung function decline during maintenance therapy

The association between previous and future severe exacerbations of chronic obstructive pulmonary disease: Updating the literature using robust statistical methodology

CRP, Fibrinogen, White Blood Cells, and Blood Cell Indices as Prognostic Biomarkers of Future COPD Exacerbation Frequency: The TIE Cohort Study

The Long-Term Burden of COPD Exacerbations During Maintenance Therapy and Lung Function Decline

Comparison of Symptom and Risk Assessment Methods among Patients with Chronic Obstructive Pulmonary Disease